Final Program

30 SUNDAY • MAY 15
• understand the lung’s capacity for compensatory re-growth of functional alveolar
units after they are injured or lost.
In this provocative session we will explore the hypothesis that pulmonary fibrosis
biology dictates that fibrosis cannot be reversed once it is established. We will use
the very successful “mythbusters” format: leading researchers will give talks relevant
to this hypothesis, after which expert “mythbusters” will discuss its validity. The
session will end with an audience vote on the validity of the hypothesis. We hope to
pair this session with another mythbusters session exploring the clinical implications
of this hypothesis: that the best that we can hope to achieve with new therapies for
fibrotic lungs diseases is the prevention of progression.
Chairing: M.R.J. Kolb, MD, PhD, Hamilton, Canada
M. Konigshoff, MD, PhD, Munich, Germany
A.M. Tager, MD, Charlestown, MA
9:00 A Patient’s Perspective
S. Rock, Rancho Murieta, CA
9:05 Once a Myofibroblast, Always a Myofibroblast? Can Lung
Myofibroblasts Revert Like They Do in the Liver?
T. Kisseleva, MD, PhD, La Jolla, CA
9:25 Targeting Matrix Cross-Linking: The Achilles Heel of Fibrosis?
P.J. Sime, MD, Rochester, NY
9:45 Turning Fibrosis Down a Notch while Turning Up
Regeneration: Progenitor Cell Notch Signaling Determines
Outcome of Lung Injury
H. Chapman, MD, San Francisco, CA
10:05 Busting the Myth that the Lung Cannot Regenerate
B. Ding, PhD, New York, NY
10:25 Panel Discussion
G. Laurent, PhD, Nedlands, Australia
J. Gauldie, PhD, Hamilton, Canada
Z. Borok, MD, Los Angeles, CA
There will be a 5-minute discussion after each talk.
This session and the International Conference are supported by an educational grant from
Boehringer Ingelheim Pharmaceuticals, Inc.
All CME sessions have been planned and implemented in accordance with the Essential
Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME)
and are free of the control of commercial interests.
A8
BASIC • CLINICAL • TRANSLATIONAL
SCIENTIFIC SYMPOSIUM
CME Credits Available: 2.0
EVERYTHING YOU EVER WANTED TO KNOW
ABOUT SEX STEROIDS AND LUNG DISEASE
Assemblies on Respiratory Structure and Function; Allergy, Immunology
and Inflammation; Pulmonary Circulation; Respiratory Cell and
Molecular Biology; Thoracic Oncology
9:00 a.m. - 11:00 a.m. MOSCONE CENTER
Room 2006/2008 (West Building, Level 2)
Target Audience
Lung health providers, trainees, and those involved in research or clinical care
related to lung disease and reproductive hormones. This topic is expected to
appeal to both scientists and clinicians.
Objectives
At the conclusion of this session, the participant will be able to:
• learn new findings about the effects of sex steroid signaling on lung structure
and function;
• apply knowledge about sex steroids to management of patients with
non-neoplastic lung diseases;
• apply knowledge about sex steroids to management of patients with lung
cancer.
Sex steroids (i.e., reproductive hormones) have biologic and pathophysiologic
actions in the lung mediated by both genomic and non-genomic mechanisms. This
session will review the biology of sex steroids and their receptors in the lung, discuss
the impact of sex steroids on lung structure and function, and explore the role of sex
steroid signaling in lung diseases with known gender differences in incidence and in
morbidity and mortality. The learner will better understand the impact of sex steroids
on disease manifestation and severity and will appreciate the potential for these
hormones as biomarkers and therapeutic targets in lung disease.
Chairing: G.S. Skloot, MD, New York, NY
Y.S. Prakash, MD, PhD, Rochester, MN
M. MacLean, PhD, Glasgow, United Kingdom
9:00 Introduction to Sex Steroid Signaling and Effects on Lung
Structure and Function
Y.S. Prakash, MD, PhD, Rochester, MN
9:25 The Role of Sex Steroid Signaling In Pulmonary Hypertension
M. MacLean, PhD, Glasgow, United Kingdom
9:50 The Role of Sex Steroid Signaling in Airway Disease
B.N. Melgert, PhD, Groningen, Netherlands
10:15 The Role of Sex Steroid Signaling In Lung Cancer
C.A. Powell, MD, New York, NY
10:40 Future Directions: Sex Steroids as Potential Biomarkers and
Therapeutic Targets
S.E. Wenzel, MD, Pittsburgh, PA
There will be a 5-minute discussion after each talk.
This session and the International Conference are supported by an educational grant from
AstraZeneca LP.
All CME sessions have been planned and implemented in accordance with the Essential
Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME)
and are free of the control of commercial interests.
A9
CLINICAL • TRANSLATIONAL
SCIENTIFIC SYMPOSIUM
CME Credits Available: 2.0
CONTROVERSIES IN SLEEP MEDICINE: DAVIDS,
GOLIATHS, AND SOME BLOOD ON THE FLOOR!
Assemblies on Sleep and Respiratory Neurobiology; Clinical Problems
9:00 a.m. - 11:00 a.m. MOSCONE CENTER
Target Audience
Sleep physicians, researchers, nurses, and trainees.
Room 3003/3005 (West Building, Level 3)
Objectives
At the conclusion of this session, the participant will be able to:
ATS 2016 • San Francisco